No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NEO240816C17500
- 0.32
- +0.07+28.00%
15min DelayClose Jul 24 15:59 ET
0.35High0.30Low
0.30Open0.25Pre Close32 Volume815 Open Interest17.50Strike Price1.00KTurnover65.46%IV17.39%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type0.2242Delta0.1193Gamma50.60Leverage Ratio-0.0166Theta0.0020Rho11.34Eff Leverage0.0115Vega
Intraday
- 5D
- Daily
News
Earnings Preview: NeoGenomics to Report Financial Results Post-market on July 29
NeoGenomics (NASDAQ:NEO) Shareholders Have Endured a 68% Loss From Investing in the Stock Three Years Ago
Is NeoGenomics, Inc. (NEO) the Most Profitable Stock of the Last 20 Years?
Express News | Neogenomics Inc : Leerink Partners Cuts Target Price to $27 From $28
NeoGenomics's Growth and Resilience Affirm Buy Rating: Analyst Puneet Souda's Perspective
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
Comments
The company's debt usage, EBIT loss, and liabilities exceeding cash and short-term receivables are worrisome. Its slow revenue growth and weak balance sheet position add to its perceived riskiness.
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
RECAP
U.S. stocks traded modestly higher Thursday, pushing the S&P 500 to within just a few points of a fresh record closing high.
The $S&P 500 Index(.SPX.US$ gained 2 points, or 0.04%, to 4,783. The $Dow Jones Industrial Average(.DJI.US$ rose by 53 points, or 0.14%, to 37,710. The $Nasdaq Composite Index(.IXIC.US$ fell 4 points, or 0.03%, to 15,095.
U.S. stocks opened higher as the penultimate trading session of 2023 got un...
U.S. stocks traded modestly higher Thursday, pushing the S&P 500 to within just a few points of a fresh record closing high.
The $S&P 500 Index(.SPX.US$ gained 2 points, or 0.04%, to 4,783. The $Dow Jones Industrial Average(.DJI.US$ rose by 53 points, or 0.14%, to 37,710. The $Nasdaq Composite Index(.IXIC.US$ fell 4 points, or 0.03%, to 15,095.
U.S. stocks opened higher as the penultimate trading session of 2023 got un...
23
2
The company's high P/S ratio and future revenue predictions may not sustain the positive sentiment, putting shareholder investments and potential investors at risk of overpayment.
Despite a solid market capitalization, concerns arise from the EBIT level loss, liabilities against cash, and a US$50m cash burn over the last year. Slow growth rate also increases perceived risk for future performance.
Despite past year's lack of profitability and modest revenue growth, investor sentiment towards the future bolsters the stock. While long-term loss over five years persists, short-term return suggests a potential brighter future for NeoGenomics, Inc., albeit with identified risks.
Read more